Henry Schein (NASDAQ:HSIC) Director William Daniel Purchases 10,000 Shares

Henry Schein, Inc. (NASDAQ:HSIC) Director William Daniel acquired 10,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the acquisition, the director owned 20,000 shares of the company’s stock, valued at $1,383,800. This represents a 100.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Henry Schein Stock Up 0.5%

HSIC stock opened at $69.35 on Wednesday. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a twelve month low of $61.94 and a twelve month high of $89.29. The company’s 50 day moving average is $75.33 and its two-hundred day moving average is $75.17. The stock has a market cap of $7.90 billion, a P/E ratio of 20.95, a PEG ratio of 1.73 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. The business had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts expect that Henry Schein, Inc. will post 5.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Henry Schein

Several institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its position in shares of Henry Schein by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock worth $211,734,000 after buying an additional 56,687 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Henry Schein by 12.7% in the 1st quarter. Parallel Advisors LLC now owns 1,314 shares of the company’s stock worth $97,000 after buying an additional 148 shares in the last quarter. SEB Asset Management AB purchased a new stake in shares of Henry Schein in the 1st quarter worth about $2,276,000. Bessemer Group Inc. boosted its position in shares of Henry Schein by 9.8% in the 1st quarter. Bessemer Group Inc. now owns 6,990 shares of the company’s stock worth $515,000 after buying an additional 626 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Henry Schein by 0.6% in the 1st quarter. Bank of New York Mellon Corp now owns 545,599 shares of the company’s stock worth $40,211,000 after buying an additional 3,380 shares in the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HSIC. Morgan Stanley reaffirmed an “underweight” rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Wells Fargo & Company lifted their target price on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a research report on Wednesday, May 6th. Citigroup began coverage on shares of Henry Schein in a report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 target price on the stock. Finally, Barrington Research set a $97.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Henry Schein has an average rating of “Hold” and a consensus price target of $86.83.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.